The inhibition study of human UDP-glucuronosyltransferases with cytochrome P450 selective substrates and inhibitors

References

• Hasler JA. Pharmacogenetics of cytochromes P450. Mol Aspects Med 1999;20:12–24, 5–137.
   PubMedGoogle Scholar
• Radominska-Pandya A, Czernik PJ, Little JM, Battaglia E, Mackenzie PI. Structural and functional studies of UDP-glucuronosyltransferases. Drug Metab Rev 1999;31:817–899.
   PubMed Web of Science ®Google Scholar
• Pasternak GW, Bodnar RJ, Clark JA, Inturrisi CE. Morphine-6-glucuronide, a potent mu agonist. Life Sci 1987;41:2845–2849.
   PubMed Web of Science ®Google Scholar
• Radominska-Pandya A, Bratton S, Little JM. A historical overview of the heterologous expression of mammalian UDP-glucuronosyltransferase isoforms over the past twenty years. Curr Drug Metab 2005;6:141–160.
   PubMed Web of Science ®Google Scholar
• Terrier N, Benoit E, Senay C, Lapicque F, Radominska-Pandya A, Magdalou J, Fournel-Gigleux S. Human and rat liver UDP-glucuronosyltransferases are targets of ketoprofen acylglucuronide. Mol Pharmacol 1999;56:226–234.
   PubMed Web of Science ®Google Scholar
• Shipkova M, Armstrong VW, Oellerich M, Wieland E. Acyl glucuronide drug metabolites: toxicological and analytical implications. Ther Drug Monit 2003;25:1–16.
   PubMed Web of Science ®Google Scholar
• Kadakol A, Ghosh SS, Sappal BS, Sharma G, Chowdhury JR, Chowdhury NR. Genetic lesions of bilirubin uridine-diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler–Najjar and Gilbert syndromes: correlation of genotype to phenotype. Hum Mutat 2000;16:297–306.
   PubMed Web of Science ®Google Scholar
• Guillemette C. Pharmacogenomics of human UDP-glucuronosyltransferase enzymes. Pharmacogenomics J 2003;3:136–158.
   PubMed Web of Science ®Google Scholar
• Ogilvie BW, Zhang D, Li W, Rodrigues AD, Gipson AE, Holsapple J, Toren P, Parkinson A. Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug Metab Dispos 2006;34:191–197.
   PubMed Web of Science ®Google Scholar
• Backman JT, Kyrklund C, Neuvonen M, Neuvonen PJ. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther 2002;72:685–691.
   PubMed Web of Science ®Google Scholar
• Benbrik E, Chariot P, Bonavaud S, Ammi-Saïd M, Frisdal E, Rey C, Gherardi R, Barlovatz-Meimon G. Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddI) and zalcitabine (ddC) on cultured human muscle cells. J Neurol Sci 1997;149:19–25.
   PubMed Web of Science ®Google Scholar
• Trapnell CB, Klecker RW, Jamis-Dow C, Collins JM. Glucuronidation of 3′-azido-3′-deoxythymidine (zidovudine) by human liver microsomes: relevance to clinical pharmacokinetic interactions with atovaquone, fluconazole, methadone, and valproic acid. Antimicrob Agents Chemother 1998;42:1592–1596.
   PubMed Web of Science ®Google Scholar
• Barbier O, Turgeon D, Girard C, Green MD, Tephly TR, Hum DW, Bélanger A. 3′-azido-3′-deoxythimidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 2B7 (UGT2B7). Drug Metab Dispos 2000;28:497–502.
   PubMed Web of Science ®Google Scholar
• Nguyen N, Tukey RH. Baculovirus-directed expression of rabbit UDP-glucuronosyltransferases in Spodoptera frugiperda cells. Drug Metab Dispos 1997;25:745–749.
   Google Scholar
• Yueh MF, Nguyen N, Famourzadeh M, Strassburg CP, Oda Y, Guengerich FP, Tukey RH. The contribution of UDP-glucuronosyltransferase 1A9 on CYP1A2-mediated genotoxicity by aromatic and heterocyclic amines. Carcinogenesis 2001;22:943–950.
   PubMed Web of Science ®Google Scholar
• Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265–275.
   PubMed Web of Science ®Google Scholar
• Yao M, Zhu M, Sinz MW, Zhang H, Humphreys WG, Rodrigues AD, Dai R. Development and full validation of six inhibition assays for five major cytochrome P450 enzymes in human liver microsomes using an automated 96-well microplate incubation format and LC-MS/MS analysis. J Pharm Biomed Anal 2007;44:211–223.
   PubMed Web of Science ®Google Scholar
• Soars MG, Mattiuz EL, Jackson DA, Kulanthaivel P, Ehlhardt WJ, Wrighton SA. Biosynthesis of drug glucuronides for use as authentic standards. J Pharmacol Toxicol Methods 2002;47:161–168.
   Google Scholar
• Fisher MB, Campanale K, Ackermann BL, VandenBranden M, Wrighton SA. In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin. Drug Metab Dispos 2000;28:560–566.
   PubMed Web of Science ®Google Scholar
• Klieber S, Hugla S, Ngo R, Arabeyre-Fabre C, Meunier V, Sadoun F, Fedeli O, Rival M, Bourrie M, Guillou F, Maurel P, Fabre G. Contribution of the N-glucuronidation pathway to the overall in vitro metabolic clearance of midazolam in humans. Drug Metab Dispos 2008;36:851–862.
   PubMed Web of Science ®Google Scholar
• Uchaipichat V, Mackenzie PI, Guo XH, Gardner-Stephen D, Galetin A, Houston JB, Miners JO. Human udp-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. Drug Metab Dispos 2004;32:413–423.
   PubMed Web of Science ®Google Scholar
• King C, Tang W, Ngui J, Tephly T, Braun M. Characterization of rat and human UDP-glucuronosyltransferases responsible for the in vitro glucuronidation of diclofenac. Toxicol Sci 2001;61:49–53.
   PubMed Web of Science ®Google Scholar
• Williams JA, Ring BJ, Cantrell VE, Campanale K, Jones DR, Hall SD, Wrighton SA. Differential modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1)-catalyzed estradiol-3-glucuronidation by the addition of UGT1A1 substrates and other compounds to human liver microsomes. Drug Metab Dispos 2002;30:1266–1273.
   PubMed Web of Science ®Google Scholar
• Hyland R, Osborne T, Payne A, Kempshall S, Logan YR, Ezzeddine K, Jones B. In vitro and in vivo glucuronidation of midazolam in humans. Br J Clin Pharmacol 2009;67:445–454.
   PubMed Web of Science ®Google Scholar
• Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach RS, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 2003;31:815–832.
   PubMed Web of Science ®Google Scholar
• Maresca A, Temperini C, Vu H, Pham NB, Poulsen SA, Scozzafava A, Quinn RJ, Supuran CT. Non-zinc mediated inhibition of carbonic anhydrases: coumarins are a new class of suicide inhibitors. J Am Chem Soc 2009;131:3057–3062.
   PubMed Web of Science ®Google Scholar
• Maresca A, Temperini C, Pochet L, Masereel B, Scozzafava A, Supuran CT. Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem 2010;53:335–344.
   PubMed Web of Science ®Google Scholar
• Huang YC, Colaizzi JL, Bierman RH, Woestenborghs R, Heykants J. Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers. Antimicrob Agents Chemother 1986;30:206–210.
   PubMed Web of Science ®Google Scholar
• Chu Z, Chen JS, Liau CT, Wang HM, Lin YC, Yang MH, Chen PM, Gardner ER, Figg WD, Sparreboom A. Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patients. Anticancer Drugs 2008;19:275–281.
   PubMed Web of Science ®Google Scholar
• Walsky RL, Obach RS. Validated assays for human cytochrome P450 activities. Drug Metab Dispos 2004;32:647–660.
   PubMed Web of Science ®Google Scholar
• Tang C, Lin Y, Rodrigues AD, Lin JH. Effect of albumin on phenytoin and tolbutamide metabolism in human liver microsomes: an impact more than protein binding. Drug Metab Dispos 2002;30:648–654.
   PubMed Web of Science ®Google Scholar